Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Brooding and reflective rumination among suicide attempters: cognitive vulnerability to suicidal ideation.

Surrence K, Miranda R, Marroquín BM, Chan S.

Behav Res Ther. 2009 Sep;47(9):803-8. doi: 10.1016/j.brat.2009.06.001. Epub 2009 Jun 12.

PMID:
19577225
2.

Mixed-effects Poisson regression analysis of adverse event reports: the relationship between antidepressants and suicide.

Gibbons RD, Segawa E, Karabatsos G, Amatya AK, Bhaumik DK, Brown CH, Kapur K, Marcus SM, Hur K, Mann JJ.

Stat Med. 2008 May 20;27(11):1814-33. doi: 10.1002/sim.3241.

3.

Efficacy and safety of the weight-loss drug rimonabant.

Després JP, Van Gaal L, Pi-Sunyer X, Scheen A.

Lancet. 2008 Feb 16;371(9612):555; author reply 556-7. doi: 10.1016/S0140-6736(08)60261-5. No abstract available.

PMID:
18280320
5.

Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects.

Astrup A, Greenway FL, Ling W, Pedicone L, Lachowicz J, Strader CD, Kwan R; Ecopipam Obesity Study Group.

Obesity (Silver Spring). 2007 Jul;15(7):1717-31.

6.

Risk factors for the incidence and persistence of suicide-related outcomes: a 10-year follow-up study using the National Comorbidity Surveys.

Borges G, Angst J, Nock MK, Ruscio AM, Kessler RC.

J Affect Disord. 2008 Jan;105(1-3):25-33. Epub 2007 May 16.

7.

Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.

Gadde KM, Allison DB.

Circulation. 2006 Aug 29;114(9):974-84. No abstract available. Erratum in: Circulation. 2007 May 15;115(19):e465.

8.

Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction.

Goldstein DJ, Rampey AH Jr, Potvin JH, Masica DN, Beasley CM Jr.

J Clin Psychiatry. 1993 Aug;54(8):309-16.

PMID:
8253699
Items per page

Supplemental Content

Write to the Help Desk